Analysis revealed statistically significant benefits in terms of PFS for sugemalimab with chemotherapy compared to placebo-accompanied chemotherapy in the untreated squamous and non-squamous NSCLC sufferers, irrespective of PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.